BioSpace News Archive

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees options to purchase an aggregate of 142,500 shares of BioCryst common stock on November 29, 2019 as inducements material to each employee entering into employment with BioCryst.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that Lawrence Mehren will retire from the company. Jack Phillips, the company’s Chief Operating Officer, has been unanimously appointed by the board to the position, effective February 1, 2020

Lannett Company, Inc. (NYSE: LCI) today announced positive results from the first human study evaluating insulin glargine that Lannett is developing with its strategic alliance partners within the HEC Group of companies (HEC).

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced Late Breaking Oral Communication at CTAD 2019.

Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen was published online in the journal Prenatal Diagnosis.

With more than 1.3 million members, Superior has become a statewide leader in health care

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its Breast Health Solutions suite will be available on the Nuance® AI Marketplace.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Seelos’ U.S. Patent number 10,493,023

Global Blood Therapeutics, Inc. announced that on December 1, 2019, the compensation committee of GBT’s board of directors granted 21 new employees options to purchase an aggregate of 13,000 shares of the company’s common stock with a per share exercise price of $66.50 and restricted stock units for an aggregate of 58,875 shares of the company’s common stock.

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the appointment of Rodney Young as chief financial officer effective December 2, 2019.